Turn On, Tune In, Turnover! Target Biology Impacts In Vivo Potency, Efficacy, and Clearance
Pharmacological Reviews · 2023-05 · 75 (3) · 416-462
DOI: 10.1124/pharmrev.121.000524 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacological Reviews, 2023-05. Verfasst von Johan Gabrielsson und 1 weiteren Autor:innen. Beteiligte Einrichtung: MedDoor AB, Gothenburg, Sweden (J.G.) and Pharmacilitator AB, Vallda, Sweden (S.H.) Professor.Gabrielsson@gmail.com. Hauptthemen laut MEDLINE: Drug Inverse Agonism, Drug Discovery. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 277 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Even though significant efforts have been spent in recent years to understand and define the determinants of in vivo potency and clearance, important pieces of information are still lacking. By introducing target turnover into the reasoning, we open up to further the understanding of central factors important to the optimization of translational dose-concentration-response predictions. We describe (i) new (open model) expressions of the in vivo potency and efficacy parameters, which embody target turnover, binding, and complex kinetics, also capturing full, partial, and inverse agonism and antagonism; (ii) a detailed examination of open models to show what potency and efficacy parameters have in common and how they differ; and (iii) a comprehensive literature review showing that target turnover rate varies with age, species, tissue/subregion, treatment, disease state, hormonal and nutritional state, and day-night cycle. The new open model expression, which integrates system and drug properties, shows the following. Fractional turnover rates rather than the absolute target or ligand-target complex expression determine necessary drug exposure via in vivo potency. Absolute ligand-target expression determines the need of a drug, based on the transduction ρ and in vivo efficacy parameters. The free enzyme concentration determines clearance and maximum metabolic rate. The fractional turnover rate determines time to equilibrium between substrate, free enzyme, and complex.The properties of substrate, target, and the complex demonstrate nonsaturable metabolic behavior at equilibrium. Nonlinear processes, previously referred to as capacity- and time-dependent kinetics, may occasionally have been disequilibria. Finally, the open model may pinpoint why some subjects differ in their demand of drug. SIGNIFICANCE STATEMENT: Understanding the target turnover is a central tenet in many translational dose-concentration-response predictions. New open model expressions of in vivo potency, efficacy parameter, and clearance are derived and anchored onto a comprehensive literature review showing that target turnover rate varies with age, species, tissue/subregion, treatment, disease, hormonal and nutritional state, day-night cycle, and more. Target turnover concepts will therefore significantly impact fundamental aspects of pharmacodynamics and pharmacokinetics, thereby also the basics of drug discovery, development, and optimization of clinical dosing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- MedDoor AB, Gothenburg, Sweden (J.G.) and Pharmacilitator AB, Vallda, Sweden (S.H.) Professor.Gabrielsson@gmail.com.
- MedDoor AB, Gothenburg, Sweden (J.G.) and Pharmacilitator AB, Vallda, Sweden (S.H.).
ORCID-Profile: Johan Gabrielsson
Zitieren
APA
Gabrielsson, J., & Hjorth, S. (2023). Turn On, Tune In, Turnover! Target Biology Impacts In Vivo Potency, Efficacy, and Clearance. Pharmacological Reviews, 75(3), 416-462. https://doi.org/10.1124/pharmrev.121.000524
Vancouver
Gabrielsson J, Hjorth S. Turn On, Tune In, Turnover! Target Biology Impacts In Vivo Potency, Efficacy, and Clearance. Pharmacological Reviews. 2023;75(3):416-462. doi:10.1124/pharmrev.121.000524
BibTeX
@article{Gabrielsson2023,
author = {Gabrielsson, Johan and Hjorth, Stephan},
title = {Turn On, Tune In, Turnover! Target Biology Impacts In Vivo Potency, Efficacy, and Clearance},
journal = {Pharmacological Reviews},
year = {2023},
volume = {75},
number = {3},
pages = {416--462},
doi = {10.1124/pharmrev.121.000524}
}
EUVIMED